By Colin Kellaher

 

Novartis AG and Incyte Corp. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of the blood-cancer drug Jakavi for the treatment of acute and chronic graft-versus-host disease.

The companies said the recommendation covers the treatment of patients ages 12 and up who have inadequate response to corticosteroids or other systemic therapies.

The European Commission, which generally follows the CHMP's advice, would now review the recommendation, with a decision expected within about two months.

The companies said Jakavi, if approved, would be the first JAK1/2 inhibitor available in Europe for patients with graft-versus-host disease, a condition in which donated bone marrow or stem cells attack a transplant recipient's organs.

Under a long-running collaboration, Wilmington, Del., biopharmaceutical company Incyte markets the drug as Jakafi in the U.S., while Switzerland's Novartis markets it as Jakavi outside the U.S.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

March 25, 2022 09:07 ET (13:07 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Novartis.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Novartis.